Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage For use as a female contraceptive (depot).
Marketing Status Prescription; Discontinued
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 65089-0053; 64918-1500; 60870-0475; 78206-145; 71161-147; 63190-0480; 63190-0260; 45541-1192; 64918-1906
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Heart rate increased13.14.04.002--Not Available
Heart rate irregular13.14.04.003--Not Available
Hemiplegia17.01.04.002--Not Available
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hepatic steatosis09.01.07.003; 14.08.04.005--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hereditary angioedema23.04.01.015; 10.01.05.012; 03.02.01.008--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hidradenitis23.02.03.0130.001237%Not Available
Hyperaesthesia17.02.06.0040.000825%Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperphagia19.09.01.005; 14.03.01.007; 07.01.06.0180.001237%Not Available
Hypersensitivity10.01.03.0030.021035%
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.001--
Hypertrichosis23.02.04.002--
Hypoaesthesia17.02.06.0230.092801%Not Available
Hypokinesia17.01.02.0090.002062%Not Available
Hypomenorrhoea21.01.02.002; 05.05.01.0060.025159%Not Available
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.001--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Immune system disorder10.02.01.001--Not Available
Implant site reaction12.07.02.009; 08.02.02.009--Not Available
Increased appetite08.01.09.027; 14.03.01.0030.004537%Not Available
Infection11.01.08.0020.004627%Not Available
Infertility21.03.02.0010.002475%Not Available
Infertility female21.03.02.0170.002475%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 19 Pages